Please login to the form below

Not currently logged in
Email:
Password:

AZ sees Seroquel XR patent overturned in Germany

Follows challenge by Teva, Hexal and Accord Healthcare

Germany flagGermany's Federal Patent Court has ruled a patent for AstraZeneca's antipsychotic Seroquel XR invalid after a challenge by a trio of generic drug companies.

Teva, Hexal and Accord Healthcare successfully persuaded the court to strike out the formulation patent protecting Seroquel XR (quetiapine fumarate) prolonged-release tablets.

This version of the drug is marketed as Seroquel Prolong in Germany, where it brought in $82m in the ten months to October 31, 2012.

“AstraZeneca is disappointed with the court's decision. The company remains committed to defending its intellectual property protecting Seroquel XR,” the firm said in a statement.

Seroquel has faced a number of generic challenges from companies keen to take a slice of global sales from that last year reached $5.8bn for the Seroquel franchise.

When it comes to protecting the extended release (XR) version of its antipsychotic drug AstraZeneca has had mixed results.

In March, a US court ruled the XR patent was valid, deciding that the generics companies Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals and Mylan had infringed AZ's patent.

But in the same month the legal situation turned against AZ in its home territory of the UK, where the high court deemed the Seroquel XR patent invalid.

14th November 2012

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics